{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:41:55Z","timestamp":1790804515943,"version":"4.1.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T00:00:00Z","timestamp":1633737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T00:00:00Z","timestamp":1633737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"national natural science foundation of china","doi-asserted-by":"publisher","award":["81974067"],"award-info":[{"award-number":["81974067"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"national natural science foundation of china","doi-asserted-by":"publisher","award":["81801601"],"award-info":[{"award-number":["81801601"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"national natural science foundation of china","doi-asserted-by":"publisher","award":["81671598"],"award-info":[{"award-number":["81671598"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s40744-021-00382-0","type":"journal-article","created":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T16:09:44Z","timestamp":1633882184000},"page":"1535-1549","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Esophageal Dysfunction in Systemic Sclerosis: An Update"],"prefix":"10.1007","volume":"8","author":[{"given":"Bo","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincheng","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuchang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,9]]},"reference":[{"issue":"8","key":"382_CR1","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nrgastro.2016.99","volume":"13","author":"AJ Emmanuel","year":"2016","unstructured":"Emmanuel AJ. Current management of the gastrointestinal complications of systemic sclerosis. Nat Rev Gastroenterol Hepatol. 2016;13(8):461\u201372.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"382_CR2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11938-008-0008-8","volume":"11","author":"EC Ebert","year":"2008","unstructured":"Ebert EC. Esophageal disease in progressive systemic sclerosis. Curr Treat Options Gastroenterol. 2008;11(1):64\u20139.","journal-title":"Curr Treat Options Gastroenterol"},{"issue":"5","key":"382_CR3","first-page":"498","volume":"30","author":"Y Alastal","year":"2017","unstructured":"Alastal Y, Hammad TA, Renno A et al. Gastrointestinal manifestations associated with systemic sclerosis: results from the nationwide inpatient sample. Ann Gastroenterol. 2017;30(5):498.","journal-title":"Ann Gastroenterol"},{"issue":"12","key":"382_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/dote\/dox067","volume":"30","author":"N Aggarwal","year":"2017","unstructured":"Aggarwal N, Lopez R, Gabbard S, Wadhwa N, Devaki P, Thota PN. Spectrum of esophageal dysmotility in systemic sclerosis on high-resolution esophageal manometry as defined by Chicago classification. Dis Esophagus. 2017;30(12):1\u20136.","journal-title":"Dis Esophagus"},{"issue":"5","key":"382_CR5","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3899\/jrheum.110923","volume":"39","author":"J Vischio","year":"2012","unstructured":"Vischio J, Saeed F, Karimeddini M, et al. Progression of esophageal dysmotility in systemic sclerosis. J Rheumatol. 2012;39(5):986\u201391.","journal-title":"J Rheumatol"},{"issue":"5","key":"382_CR6","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1442-2050.2010.01150.x","volume":"24","author":"S Roman","year":"2011","unstructured":"Roman S, Hot A, Fabien N, et al. Esophageal dysmotility associated with systemic sclerosis: a high-resolution manometry study. Dis Esophagus. 2011;24(5):299\u2013304.","journal-title":"Dis Esophagus"},{"issue":"11","key":"382_CR7","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U","volume":"43","author":"VD Steen","year":"2000","unstructured":"Steen VD, Medsger TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000;43(11):2437\u201344.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"382_CR8","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.3899\/jrheum.111582","volume":"39","author":"PD Sampaio-Barros","year":"2012","unstructured":"Sampaio-Barros PD, Bortoluzzo AB, Marangoni RG, et al. Survival, causes of death, and prognostic factors in systemic sclerosis: analysis of 947 Brazilian patients. J Rheumatol. 2012;39(10):1971\u20138.","journal-title":"J Rheumatol"},{"issue":"12","key":"382_CR9","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1136\/gut.2005.086074","volume":"55","author":"CG Roberts","year":"2006","unstructured":"Roberts CG, Hummers LK, Ravich WJ, Wigley FM, Hutchins GM. A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma). Gut. 2006;55(12):1697\u2013703.","journal-title":"Gut"},{"issue":"1","key":"382_CR10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0016-5085(93)90007-Y","volume":"105","author":"LS Miller","year":"1993","unstructured":"Miller LS, Liu JB, Klenn PJ, et al. Endoluminal ultrasonography of the distal esophagus in systemic sclerosis. Gastroenterology. 1993;105(1):31\u20139.","journal-title":"Gastroenterology"},{"issue":"3","key":"382_CR11","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/0002-9343(69)90044-8","volume":"46","author":"WA D\u2019Angelo","year":"1969","unstructured":"D\u2019Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med. 1969;46(3):428\u201340.","journal-title":"Am J Med"},{"issue":"3","key":"382_CR12","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1172\/JCI31139","volume":"117","author":"J Varga","year":"2007","unstructured":"Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007;117(3):557\u201367.","journal-title":"J Clin Invest"},{"issue":"2","key":"382_CR13","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s12016-008-8106-x","volume":"36","author":"FM Wigley","year":"2009","unstructured":"Wigley FM. Vascular disease in scleroderma. Clin Rev Allergy Immunol. 2009;36(2):150\u201375.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"8","key":"382_CR14","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/nmo.12813","volume":"28","author":"JN Kimmel","year":"2016","unstructured":"Kimmel JN, Carlson DA, Hinchcliff M, et al. The association between systemic sclerosis disease manifestations and esophageal high-resolution manometry parameters. Neurogastroenterol Motil. 2016;28(8):1157\u201365.","journal-title":"Neurogastroenterol Motil"},{"issue":"11","key":"382_CR15","first-page":"950","volume":"54","author":"S Kuribayashi","year":"2019","unstructured":"Kuribayashi S. Relationship between esophageal motility abnormalities and skin or lung involvements in patients with systemic sclerosis. JGH Open. 2019;54(11):950\u201362.","journal-title":"JGH Open"},{"issue":"1","key":"382_CR16","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s13075-015-0695-1","volume":"17","author":"JN Taroni","year":"2015","unstructured":"Taroni JN, Martyanov V, Huang CC, et al. Molecular characterization of systemic sclerosis esophageal pathology identifies inflammatory and proliferative signatures. Arthritis Res Ther. 2015;17(1):194.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"382_CR17","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s10067-018-4026-1","volume":"37","author":"S Vettori","year":"2018","unstructured":"Vettori S, Tolone S, Capocotta D, et al. Esophageal high-resolution impedance manometry alterations in asymptomatic patients with systemic sclerosis: prevalence, associations with disease features, and prognostic value. Clin Rheumatol. 2018;37(5):1239\u201347.","journal-title":"Clin Rheumatol"},{"issue":"9","key":"382_CR18","first-page":"1164","volume":"71","author":"ZH McMahan","year":"2019","unstructured":"McMahan ZH, Domsic RT, Zhu L, Medsger TA, Casciola-Rosen L, Shah AA. Anti-RNPC-3 (U11\/U12) antibodies in systemic sclerosis in patients with moderate-to-severe gastrointestinal dysmotility. Neurogastroenterol Motil. 2019;71(9):1164\u201370.","journal-title":"Neurogastroenterol Motil"},{"issue":"1","key":"382_CR19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11926-011-0217-3","volume":"14","author":"G Gyger","year":"2012","unstructured":"Gyger G, Baron M. Gastrointestinal manifestations of scleroderma: recent progress in evaluation, pathogenesis, and management. Curr Rheumatol Rep. 2012;14(1):22\u20139.","journal-title":"Curr Rheumatol Rep"},{"issue":"8","key":"382_CR20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11926-019-0841-x","volume":"21","author":"M-P T\u00e9treault","year":"2019","unstructured":"T\u00e9treault M-P, Kahrilas P. GI manifestations with a focus on the esophagus: recent progress in understanding pathogenesis. Curr Rheumatol Rep. 2019;21(8):42.","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"382_CR21","volume":"2011","author":"M Lahcene","year":"2011","unstructured":"Lahcene M, Oumnia N, Matougui N, Boudjella M, Touchene B. Esophageal involvement in scleroderma: clinical, endoscopic, and manometric features. ISRN Rheumatol. 2011;2011(4):325826.","journal-title":"ISRN Rheumatol"},{"issue":"3","key":"382_CR22","first-page":"206","volume":"3","author":"MB Adarsh","year":"2019","unstructured":"Adarsh MB. Esophageal manometry, esophagogastroduodenoscopy, and duodenal mucosal histopathology in systemic sclerosis. Rev Assoc Med Bras (1992). 2019;3(3):206\u20139.","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"382_CR23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12876-015-0241-2","volume":"15","author":"T Arif","year":"2015","unstructured":"Arif T, Masood Q, Singh J, Hassan I. Assessment of esophageal involvement in systemic sclerosis and morphea (localized scleroderma) by clinical, endoscopic, manometric and pH metric features: a prospective comparative hospital based study. BMC Gastroenterol. 2015;15:24.","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"382_CR24","first-page":"193","volume":"82","author":"NPY L\u00f3pez","year":"2017","unstructured":"L\u00f3pez NPY, Lugo-Zamudio G, Barbosa-Cobos RE, Wong-Lam A, Torres-L\u00f3pez E. Frequency of motor alterations detected through manometry in patients with esophageal symptoms and scleroderma. Rev Gastroenterol Mex. 2017;82(2):193.","journal-title":"Rev Gastroenterol Mex"},{"key":"382_CR25","doi-asserted-by":"crossref","unstructured":"Tang DM, Pathikonda M, Harrison M, Fisher RS, Friedenberg FK, Parkman HP. Symptoms and esophageal motility based on phenotypic findings of scleroderma. 2013;26(2):197\u2013203.","DOI":"10.1111\/j.1442-2050.2012.01349.x"},{"key":"382_CR26","doi-asserted-by":"publisher","unstructured":"Cozzi F, Zucchetta P, Durigon N, et al. Esophageal dysmotility in scleroderma patients with different disease forms and ANA patterns: a scintigraphic study in 100 cases. Reumatismo. 2003;55(2):86\u201392. https:\/\/doi.org\/10.4081\/reumatismo.2003.86.","DOI":"10.4081\/reumatismo.2003.86"},{"key":"382_CR27","doi-asserted-by":"crossref","unstructured":"Gyawali CP, Kahrilas PJ, Savarino E, et al. Modern diagnosis of GERD: the Lyon Consensus. 2018;67(7):1351\u201362.","DOI":"10.1136\/gutjnl-2017-314722"},{"key":"382_CR28","first-page":"2","volume":"2","author":"W Matthew","year":"2019","unstructured":"Matthew W, Emma W, Dorothy L, Sandra L, Michael C. White esophageal lesions in a patient with scleroderma: epidermoid metaplasia. Gastroenterol Rep. 2019;2:2.","journal-title":"Gastroenterol Rep"},{"issue":"3","key":"382_CR29","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4103\/0970-2113.116236","volume":"30","author":"A Chatterjee","year":"2013","unstructured":"Chatterjee A, Chaudhury S. A rare case of interaorticobronchial diverticulum of esophagus in a case of scleroderma. Lung India. 2013;30(3):222.","journal-title":"Lung India"},{"issue":"1","key":"382_CR30","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13480","volume":"31","author":"S B\u00fctikofer","year":"2019","unstructured":"B\u00fctikofer S, Jordan S, Sauter M, et al. Abnormal esophageal motility during a solid test meal in systemic sclerosis\u2014detection even in very early disease and association with disease progression. Neurogastroenterol Motil. 2019;31(1):e13480.","journal-title":"Neurogastroenterol Motil"},{"issue":"4","key":"382_CR31","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1155\/2010\/179264","volume":"17","author":"SA Charles","year":"2010","unstructured":"Charles SA, Nicole B, Luc L. Lung atelectasis secondary to massive esophageal dilation in a patient with scleroderma. Can Respir J. 2010;17(4):96\u20138.","journal-title":"Can Respir J"},{"issue":"4","key":"382_CR32","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1620\/tjem.237.345","volume":"237","author":"T Daisuke","year":"2015","unstructured":"Daisuke T, Arami S, Sheppard TJ, et al. Computed tomography of the esophagus in scleroderma and lung disease. Tohoku J Exp Med. 2015;237(4):345\u201352.","journal-title":"Tohoku J Exp Med"},{"issue":"6","key":"382_CR33","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/1346-8138.14162","volume":"45","author":"Y Asano","year":"2018","unstructured":"Asano Y, Jinnin M, Kawaguchi Y, et al. Diagnostic criteria, severity classification and guidelines of systemic sclerosis. J Dermatol. 2018;45(6):633\u201391.","journal-title":"J Dermatol"},{"issue":"2","key":"382_CR34","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3390\/jcm10020248","volume":"10","author":"K Rutka","year":"2021","unstructured":"Rutka K, Garkowski A, Karaszewska K, \u0141ebkowska U. Imaging in diagnosis of systemic sclerosis. J Clin Med. 2021;10(2):248.","journal-title":"J Clin Med"},{"key":"382_CR35","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/978-3-319-31407-5_30","volume-title":"Scleroderma","author":"JO Clarke","year":"2017","unstructured":"Clarke JO, Pandolfino JE. Upper gastrointestinal tract: manifestations of systemic sclerosis. In: Varga J, Denton C, Wigley F, Allanore Y, Kuwana M. (eds) Scleroderma. Cham: Springer; 2017, pp. 427\u201341. https:\/\/doi.org\/10.1007\/978-3-319-31407-5_30."},{"issue":"4","key":"382_CR36","first-page":"374","volume":"29","author":"T Arif","year":"2019","unstructured":"Arif T, Adil M, Sodhi JS. Upper gastrointestinal endoscopy in systemic sclerosis: A cross sectional study. J Pak Assoc Dermatol. 2019;29(4):374\u201383.","journal-title":"J Pak Assoc Dermatol"},{"issue":"2","key":"382_CR37","first-page":"165","volume":"31","author":"K Denaxas","year":"2018","unstructured":"Denaxas K, Ladas SD, Karamanolis GP. Evaluation and management of esophageal manifestations in systemic sclerosis. Ann Gastroenterol. 2018;31(2):165.","journal-title":"Ann Gastroenterol"},{"issue":"3","key":"382_CR38","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/17474124.2019.1561274","volume":"13","author":"A Chwiesko","year":"2019","unstructured":"Chwiesko A, Kowal-Bielecka O, Sierakowski S. Perspectives on the interlinked nature of systemic sclerosis and reflux disease. Expert Rev Gastroenterol Hepatol. 2019;13(3):213\u201327.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"1","key":"382_CR39","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s10620-007-9845-x","volume":"53","author":"I Mainie","year":"2008","unstructured":"Mainie I, Tutuian R, Patel A, Castell DO. Regional esophageal dysfunction in scleroderma and achalasia using multichannel intraluminal impedance and manometry. Dig Dis Sci. 2008;53(1):210\u20136.","journal-title":"Dig Dis Sci"},{"issue":"3","key":"382_CR40","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/jgh3.12138","volume":"3","author":"MB Adarsh","year":"2019","unstructured":"Adarsh MB, Sharma SK, Prasad KK, Dhir V, Singh S, Sinha SK. Esophageal manometry, esophagogastroduodenoscopy, and duodenal mucosal histopathology in systemic sclerosis. JGH Open. 2019;3(3):206\u20139.","journal-title":"JGH Open"},{"issue":"1","key":"382_CR41","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1590\/1806-9282.66.1.48","volume":"66","author":"J Markus","year":"2020","unstructured":"Markus J, Pinto RMC, Matoso AGB, Ranza R. Esophageal manometry in systemic sclerosis: findings and association with clinical manifestations. Rev Assoc Med Bras (1992). 2020;66(1):48\u201354.","journal-title":"Rev Assoc Med Bras (1992)"},{"issue":"1","key":"382_CR42","first-page":"1005","volume":"3","author":"H Poormoghim","year":"2019","unstructured":"Poormoghim H, Dodangheh S, Yaseri H, Jalali A, Andalib E. Disorder by high resolution manometry in systemic sclerosis: association with clinical features. SM Rheumatol. 2019;3(1):1005.","journal-title":"SM Rheumatol"},{"issue":"1","key":"382_CR43","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10067-019-04794-w","volume":"39","author":"W Schutyser","year":"2020","unstructured":"Schutyser W, Cruyt L, Vulsteke JB, Lenaerts JL, De Langhe E. The role of high-resolution manometry in the assessment of upper gastrointestinal involvement in systemic sclerosis: a systematic review. Clin Rheumatol. 2020;39(1):149\u201357.","journal-title":"Clin Rheumatol."},{"issue":"8","key":"382_CR44","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11894-017-0576-7","volume":"19","author":"WOA Rohof","year":"2017","unstructured":"Rohof WOA, Bredenoord AJ. Chicago classification of esophageal motility disorders: lessons learned. Curr Gastroenterol Rep. 2017;19(8):37.","journal-title":"Curr Gastroenterol Rep"},{"issue":"1","key":"382_CR45","volume":"31","author":"SI Motegi","year":"2019","unstructured":"Motegi SI, Jordan S, Sauter M, et al. Abnormal esophageal motility during a solid test meal in systemic sclerosis-detection even in very early disease and association with disease progression. J Gastroenterol. 2019;31(1):e13480","journal-title":"J Gastroenterol."},{"issue":"8","key":"382_CR46","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/art.1780290821","volume":"29","author":"F Jean","year":"1986","unstructured":"Jean F, Aubert A, Bloch F, et al. Effects of diltiazem versus nifedipine on lower esophageal sphincter pressure in patients with progressive systemic sclerosis. Arthritis Rheum. 1986;29(8):1054\u20135.","journal-title":"Arthritis Rheum."},{"issue":"10","key":"382_CR47","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/art.24734","volume":"61","author":"S Assassi","year":"2009","unstructured":"Assassi S, Del Junco D, Sutter K, et al. Clinical and genetic factors predictive of mortality in early systemic sclerosis. Arthritis Rheum. 2009;61(10):1403\u201311.","journal-title":"Arthritis Rheum."},{"issue":"10","key":"382_CR48","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/rheumatology\/kes160","volume":"51","author":"E Harrison","year":"2012","unstructured":"Harrison E, Herrick AL, McLaughlin JT, Lal S. Malnutrition in systemic sclerosis. Rheumatology (Oxford). 2012;51(10):1747\u201356.","journal-title":"Rheumatology (Oxford)."},{"issue":"3","key":"382_CR49","first-page":"135","volume":"8","author":"MA Recasens","year":"2012","unstructured":"Recasens MA, Puig C, Ortiz-Santamaria V. Nutrition in systemic sclerosis. Reumatol Clin. 2012;8(3):135\u201340.","journal-title":"Reumatol Clin"},{"issue":"1","key":"382_CR50","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s40674-014-0005-0","volume":"1","author":"V Nagaraja","year":"2015","unstructured":"Nagaraja V, McMahan ZH, Getzug T, Khanna D. Management of gastrointestinal involvement in scleroderma. Curr Treat Options Rheumatol. 2015;1(1):82\u2013105.","journal-title":"Curr Treat Options Rheumatol."},{"issue":"5","key":"382_CR51","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2036.1991.tb00516.x","volume":"5","author":"L Hendel","year":"1991","unstructured":"Hendel L. Hydroxyproline in the oesophageal mucosa of patients with progressive systemic sclerosis during omeprazole-induced healing of reflux oesophagitis. Aliment Pharmacol Ther. 1991;5(5):471\u201380.","journal-title":"Aliment Pharmacol Ther"},{"issue":"16","key":"382_CR52","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1080\/14656566.2020.1793960","volume":"21","author":"ZH McMahan","year":"2020","unstructured":"McMahan ZH, Volkmann ER. An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis. Expert Opin Pharmacother. 2020;21(16):2041\u201356.","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"382_CR53","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF02811072","volume":"26","author":"T Horikoshi","year":"1991","unstructured":"Horikoshi T, Sekiguchi T, Kusano M, Matsuzaki T. Effects of famotidine on upper gastrointestinal motility in patients with progressive systemic sclerosis. Gastroenterol Jpn. 1991;26(2):145\u201350.","journal-title":"Gastroenterol Jpn."},{"issue":"7","key":"382_CR54","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/apt.15438","volume":"50","author":"S Han","year":"2019","unstructured":"Han S, Choi HY, Kim YH, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects. J Aliment Pharmacol Ther. 2019;50(7):751\u20139.","journal-title":"J Aliment Pharmacol Ther"},{"issue":"2","key":"382_CR55","first-page":"1","volume":"14","author":"M Tabuchi","year":"2021","unstructured":"Tabuchi M, Minami H, Akazawa Y, et al. Use of vonoprazan for management of systemic sclerosis-related gastroesophageal reflux disease. Biomed Rep. 2021;14(2):1\u20131.","journal-title":"Biomed Rep."},{"key":"382_CR56","first-page":"44","volume":"27","author":"JL Tandaipan","year":"2020","unstructured":"Tandaipan JL, Castellv\u00ed IJ. Systemic sclerosis and gastrointestinal involvement. Rev Colombiana Reumatol (English Edition). 2020;27:44\u201354.","journal-title":"Rev Colomb Reumatol (English Edition)"},{"issue":"6","key":"382_CR57","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/RHU.0000000000000626","volume":"24","author":"JB Miller","year":"2018","unstructured":"Miller JB, Gandhi N, Clarke J, McMahan Z. Gastrointestinal involvement in systemic sclerosis: an update. J Clin Rheumatol. 2018;24(6):328.","journal-title":"J Clin Rheumatol."},{"issue":"1","key":"382_CR58","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s100670200010","volume":"21","author":"SJ Wang","year":"2002","unstructured":"Wang SJ, La JL, Chen DY, Chen YH, Hsieh TY, Lin WY. Effects of cisapride on oesophageal transit of solids in patients with progressive systemic sclerosis. Clin Rheumatol. 2002;21(1):43\u20135.","journal-title":"Clin Rheumatol."},{"issue":"2","key":"382_CR59","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/rheumatology\/kew216","volume":"56","author":"C Foocharoen","year":"2017","unstructured":"Foocharoen C, Chunlertrith K, Mairiang P, et al. Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial. Rheumatology (Oxford). 2017;56(2):214\u201322.","journal-title":"Rheumatology (Oxford)."},{"key":"382_CR60","doi-asserted-by":"publisher","first-page":"108","DOI":"10.11604\/pamj-cm.2020.2.108.21950","volume":"2","author":"S Ghani","year":"2020","unstructured":"Ghani S, Serraj I, Salihoun M, Acharki M, Kabbaj N. Esophageal motility disorders in systemic sclerosis. PAMJ Clin Med. 2020;2:108. https:\/\/doi.org\/10.11604\/pamj-cm.2020.2.108.21950.","journal-title":"PAMJ Clin Med"},{"issue":"1","key":"382_CR61","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13075-016-1094-y","volume":"18","author":"GP Karamanolis","year":"2016","unstructured":"Karamanolis GP, Panopoulos S, Denaxas K, et al. The 5-HT1A receptor agonist buspirone improves esophageal motor function and symptoms in systemic sclerosis: a 4-week, open-label trial. Arthritis Res Ther. 2016;18(1):195.","journal-title":"Arthritis Res Ther."},{"issue":"7","key":"382_CR62","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.3748\/wjg.v21.i7.2067","volume":"21","author":"M Nobre e Souza","year":"2015","unstructured":"Nobre e Souza M\u00c2, Bezerra PC, Nobre RA, da Fonseca Holanda ES, dos Santos AA. Increased inspiratory esophagogastric junction pressure in systemic sclerosis: an add-on to antireflux barrier. World J Gastroenterol. 2015;21(7):2067\u201372.","journal-title":"World J Gastroenterol"},{"key":"382_CR63","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijscr.2017.06.020","volume":"37","author":"A Andrade","year":"2017","unstructured":"Andrade A, Folstein MK, Davis BR. Case report of robotic dor fundoplication for scleroderma esophagus with aperistalsis on manometry. Int J Surg Case Rep. 2017;37:69\u201371.","journal-title":"Int J Surg Case Rep"},{"issue":"9","key":"382_CR64","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1007\/s00464-018-6115-2","volume":"32","author":"J Yan","year":"2018","unstructured":"Yan J, Strong AT, Sharma G, et al. Surgical management of gastroesophageal reflux disease in patients with systemic sclerosis. Surg Endosc. 2018;32(9):3855\u201360.","journal-title":"Surg Endosc."},{"issue":"5","key":"382_CR65","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s10620-006-9257-3","volume":"52","author":"H Sallam","year":"2007","unstructured":"Sallam H, McNearney TA, Doshi D, Chen JD. Transcutaneous electrical nerve stimulation (TENS) improves upper GI symptoms and balances the sympathovagal activity in scleroderma patients. Dig Dis Sci. 2007;52(5):1329.","journal-title":"Dig Dis Sci."},{"key":"382_CR66","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1196\/annals.1423.070","volume":"1110","author":"A Abou-Raya","year":"2007","unstructured":"Abou-Raya A, Abou-Raya S, Helmii M. Statins as immunomodulators in systemic sclerosis. Ann NY Acad Sci. 2007;1110:670\u201380.","journal-title":"Ann NY Acad Sci"},{"issue":"2","key":"382_CR67","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10753-018-0907-3","volume":"42","author":"RSG Gon\u00e7alves","year":"2019","unstructured":"Gon\u00e7alves RSG, Dantas AT, Pereira MC, et al. Statins inhibit cytokines in a dose-dependent response in patients with systemic sclerosis. Inflammation. 2019;42(2):407\u201311.","journal-title":"Inflammation."},{"issue":"9","key":"382_CR68","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/acr.22018","volume":"65","author":"T Tingey","year":"2013","unstructured":"Tingey T, Shu J, Smuczek J, Pope J. Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. Arthritis Care Res (Hoboken). 2013;65(9):1460\u201371.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"5","key":"382_CR69","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/rheumatology\/keq003","volume":"49","author":"HY Sadik","year":"2010","unstructured":"Sadik HY, Moore TL, Vail A, et al. Lack of effect of 8 weeks atorvastatin on microvascular endothelial function in patients with systemic sclerosis. Rheumatology (Oxford). 2010;49(5):990\u20136.","journal-title":"Rheumatology (Oxford)."},{"issue":"6","key":"382_CR70","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/jcph.1574","volume":"60","author":"A Guigui","year":"2020","unstructured":"Guigui A, Mazet R, Blaise S, et al. Treprostinil hydrogel iontophoresis in systemic sclerosis-related digital skin ulcers: a safety study. J Clin Pharmacol. 2020;60(6):758\u201367.","journal-title":"J Clin Pharmacol."},{"issue":"6","key":"382_CR71","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/acr.21622","volume":"64","author":"A Fava","year":"2012","unstructured":"Fava A, Wung PK, Wigley FM, et al. Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud\u2019s phenomenon. Arthritis Care Res (Hoboken). 2012;64(6):925\u20139.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"1","key":"382_CR72","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3109\/01902148.2016.1141263","volume":"42","author":"Y Bei","year":"2016","unstructured":"Bei Y, Hua-Huy T, Nicco C, et al. RhoA\/Rho-kinase activation promotes lung fibrosis in an animal model of systemic sclerosis. Exp Lung Res. 2016;42(1):44\u201355.","journal-title":"Exp Lung Res."},{"issue":"1","key":"382_CR73","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s13075-015-0721-3","volume":"17","author":"JK Gordon","year":"2015","unstructured":"Gordon JK, Martyanov V, Magro C, et al. Nilotinib (TasignaTM) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial. Arthritis Res Ther. 2015;17(1):213.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"382_CR74","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.ajpath.2012.07.017","volume":"181","author":"P Zerr","year":"2012","unstructured":"Zerr P, Distler A, Palumbo-Zerr K, et al. Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease. Am J Pathol. 2012;181(5):1672\u201380.","journal-title":"Am J Pathol."},{"issue":"7","key":"382_CR75","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1096\/fj.07-105627","volume":"22","author":"A Akhmetshina","year":"2008","unstructured":"Akhmetshina A, Dees C, Pileckyte M, et al. Dual inhibition of c-Abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J. 2008;22(7):2214\u201322.","journal-title":"FASEB J."},{"key":"382_CR76","volume":"140","author":"C Beyer","year":"2010","unstructured":"Beyer C, Distler JH, Distler O. Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases? Swiss Med Wkly. 2010;140:w13050.","journal-title":"Swiss Med Wkly"},{"issue":"Suppl 5","key":"382_CR77","doi-asserted-by":"crossref","first-page":"v10","DOI":"10.1093\/rheumatology\/ken276","volume":"47","author":"JH Distler","year":"2008","unstructured":"Distler JH, Distler O. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis. Rheumatology (Oxford). 2008;47(Suppl 5):v10\u20131.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"382_CR78","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1093\/rheumatology\/keaa613","volume":"60","author":"H You","year":"2021","unstructured":"You H, Xu D, Hou Y, et al. Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis. Rheumatology (Oxford). 2021;60(5):2472\u20137.","journal-title":"Rheumatology (Oxford)."},{"issue":"8","key":"382_CR79","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.14876","volume":"32","author":"SC Deverapalli","year":"2018","unstructured":"Deverapalli SC, Rosmarin D. The use of JAK inhibitors in the treatment of progressive systemic sclerosis. J Eur Acad Dermatol Venereol. 2018;32(8): e328.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"382_CR80","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/03009742.2017.1387673","volume":"47","author":"T Komai","year":"2018","unstructured":"Komai T, Shoda H, Hanata N, Fujio K. Tofacitinib rapidly ameliorated polyarthropathy in a patient with systemic sclerosis. Scand J Rheumatol. 2018;47(6):505\u20136.","journal-title":"Scand J Rheumatol."},{"issue":"10","key":"382_CR81","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","volume":"8","author":"D Khanna","year":"2020","unstructured":"Khanna D, Lin CJF, Furst DE, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020;8(10):963\u201374.","journal-title":"Lancet Respir Med."},{"issue":"9","key":"382_CR82","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2018-213031","volume":"77","author":"CP Denton","year":"2018","unstructured":"Denton CP, Ong VH, Xu S, et al. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the fasscinate clinical trial in systemic sclerosis. Ann Rheum Dis. 2018;77(9):1362\u201371.","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"382_CR83","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.berh.2019.01.011","volume":"32","author":"G Zacay","year":"2018","unstructured":"Zacay G, Levy Y. Outcomes of patients with systemic sclerosis treated with tocilizumab: case series and review of the literature. Best Pract Res Clin Rheumatol. 2018;32(4):563\u201371.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"382_CR84","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.40358","volume":"70","author":"JK Gordon","year":"2018","unstructured":"Gordon JK, Martyanov V, Franks JM, et al. Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled, pilot trial. Arthritis Rheumatol. 2018;70(2):308\u201316.","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"382_CR85","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1186\/s13104-018-3994-1","volume":"11","author":"VS Vilela","year":"2018","unstructured":"Vilela VS, da Silva BRA, da Costa CH, Lopes AJ, Levy RA, Rufino R. Effects of treatment with rituximab on microcirculation in patients with long-term systemic sclerosis. BMC Res Notes. 2018;11(1):874.","journal-title":"BMC Res Notes."},{"issue":"3","key":"382_CR86","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/cei.13501","volume":"201","author":"S O'Reilly","year":"2020","unstructured":"O\u2019Reilly S, van Laar J. B(effector)reaking bad in systemic sclerosis: role of a novel B cell subset. Clin Exp Immunol. 2020;201(3):231\u20132.","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"382_CR87","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00296-020-04515-6","volume":"40","author":"DP Misra","year":"2020","unstructured":"Misra DP, Ahmed S, Agarwal V. Is biological therapy in systemic sclerosis the answer? Rheumatol Int. 2020;40(5):679\u201394.","journal-title":"Rheumatol Int"},{"issue":"4","key":"382_CR88","doi-asserted-by":"crossref","first-page":"477","DOI":"10.5056\/jnm19148","volume":"26","author":"JS Lee","year":"2020","unstructured":"Lee JS, Kim H, Moon JR, et al. Esophageal involvement and determinants of perception of esophageal symptoms among south koreans with systemic sclerosis. J Neurogastroenterol Motil. 2020;26(4):477\u201385.","journal-title":"J Neurogastroenterol Motil"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-021-00382-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-021-00382-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-021-00382-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T18:14:49Z","timestamp":1636222489000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-021-00382-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,9]]},"references-count":88,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["382"],"URL":"https:\/\/doi.org\/10.1007\/s40744-021-00382-0","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,9]]},"assertion":[{"value":"3 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}